Business Description
ODI Pharma AB
ISIN : SE0013409760
Share Class Description:
XSAT:ODI: Ordinary SharesCompare
Compare
Traded in other countries / regions
ODI.Sweden6OD.Germany IPO Date
2020-01-23Description
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.28 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -7.7 | |||||
| 3-Year FCF Growth Rate | 1.3 | |||||
| 3-Year Book Growth Rate | -49.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.24 | |||||
| 9-Day RSI | 73.32 | |||||
| 14-Day RSI | 64.66 | |||||
| 6-1 Month Momentum % | -2.83 | |||||
| 12-1 Month Momentum % | 8.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | |||||
| Quick Ratio | 1.32 | |||||
| Cash Ratio | 1.23 | |||||
| Days Inventory | 290.43 | |||||
| Days Sales Outstanding | 153.98 | |||||
| Days Payable | 269.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -120.99 | |||||
| Operating Margin % | -653.09 | |||||
| Net Margin % | -700.71 | |||||
| FCF Margin % | -457.67 | |||||
| ROE % | -117.07 | |||||
| ROA % | -54.65 | |||||
| ROIC % | -106.39 | |||||
| ROC (Joel Greenblatt) % | -1373.21 | |||||
| ROCE % | -107.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 144.74 | |||||
| PB Ratio | 41.04 | |||||
| Price-to-Tangible-Book | 43.85 | |||||
| EV-to-EBIT | -22.05 | |||||
| EV-to-EBITDA | -22.08 | |||||
| EV-to-Revenue | 141.5 | |||||
| EV-to-FCF | -29.45 | |||||
| Price-to-Net-Current-Asset-Value | 43.85 | |||||
| Price-to-Net-Cash | 71.25 | |||||
| Earnings Yield (Greenblatt) % | -4.53 | |||||
| FCF Yield % | -2.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ODI Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.567 | ||
| EPS (TTM) (kr) | -0.256 | ||
| Beta | 0 | ||
| Volatility % | 34.47 | ||
| 14-Day RSI | 64.66 | ||
| 14-Day ATR (kr) | 0.191303 | ||
| 20-Day SMA (kr) | 5.2725 | ||
| 12-1 Month Momentum % | 8.65 | ||
| 52-Week Range (kr) | 2.88 - 6.9 | ||
| Shares Outstanding (Mil) | 15.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ODI Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ODI Pharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
ODI Pharma AB Frequently Asked Questions
What is ODI Pharma AB(XSAT:ODI)'s stock price today?
The current price of XSAT:ODI is kr5.70. The 52 week high of XSAT:ODI is kr6.90 and 52 week low is kr2.88.
When is next earnings date of ODI Pharma AB(XSAT:ODI)?
The next earnings date of ODI Pharma AB(XSAT:ODI) is 2024-05-30.
Does ODI Pharma AB(XSAT:ODI) pay dividends? If so, how much?
ODI Pharma AB(XSAT:ODI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers